Prostate cancer drug interaction study completed: what it means for patients
NCT ID NCT04621669
First seen Jun 08, 2026 · Last updated Jun 18, 2026 · Updated 3 times
Summary
This study looked at how a new prostate cancer drug, SHR3680, affects the way the body processes three other common drugs (digoxin, rosuvastatin, and metformin). Thirty-six men with prostate cancer took SHR3680 along with these drugs to measure changes in drug levels and safety. The goal was to understand potential interactions to guide future dosing recommendations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hospital of Qingdao University
Qingdao, Shandong, 266003, China
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.